LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced plans to initiate additional animal stroke functional recovery studies with its lead oral drug candidate arimoclomol, currently being evaluated as a therapeutic for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). The animal studies are expected to begin in the first quarter of 2007, and CytRx anticipates results of the studies will be announced in the second quarter of 2007. In November 2006, CytRx presented data at the Rodman & Renshaw 8th Annual Healthcare Conference demonstrating for the first time that arimoclomol improved the functional recovery of motor skills in an experimental rat model of stroke.
